The construction of a complex consisting of a research and development (R&D) lab and a COVID-19 vaccine production workshop in Wuhan, Hubei, China is complete. The project, undertaken by China State Construction Engineering Corporation (CSCEC), is affiliated with the China National Biotech Group (CNBG), a subsidiary of Sinopharm.
The complex
The complex is capable of producing inactivated COVID-19 vaccine on a large scale, as well as studying pathogenic virus vaccines. It is of great significance to the R&D of COVID-19 medicines and vaccines.
Also Read: L&T Construction converts healthcare units into COVID-19 care facilities
Construction started in March with enormous support from the local government in Hubei and Wuhan. China Construction Third Engineering Bureau, a CSCEC subsidiary, overcame difficulties amid the epidemic and met the requirements of high standard and quality.
After successfully building two makeshift hospitals Huoshenshan and Leishenshan at fast speed, China Construction Third Engineering Bureau finished building the complex within just over 100 days, making it a high biosafety level vaccine production workshop for human use. The workshop can produce over 100 million doses of the inactivated COVID-19 vaccine per year. It will help to develop China’s scale production of COVID-19 vaccines, and lay a solid foundation for large-scale vaccination in the future.
